Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Research from Ludwig Oxford’s Colin Goding and Department of Oncology’s Francesca Buffa uncovers new genes regulated by MITF in the context of the melanoma tumour microenvironment.

The switching of cancer cell phenotypes in response to microenvironmental signals such as low oxygen and low nutrients is increasingly recognised as an important cause of cancer progression and resistance to therapy. In melanoma, the master transcriptional regulator MITF has a key role in phenotype switching and cells with high MITF expression are proliferative and differentiated whereas cells with low MITF expression are invasive, undifferentiated and more resistant to therapy.

Despite previous studies identifying some MITF binding signatures and target genes, these cannot explain the breadth of MITF’s role in melanoma progression and therapy resistance. In this paper published in Pigment Cell and Melanoma Research, Dr Jagat Chauhan from Professor Colin Goding’s laboratory analysed a range of molecular data (genomics, transcriptomics, chromatin immunoprecipitation sequencing and mass spectrometry) obtained from melanoma cell lines and clinical samples so that the role of the microenvironment could be considered.

This study reveals how MITF activity may suppress genes regulated by the transcription factor AP1, a driver of the undifferentiated/invasive phenotype. This may explain MITF’s ability to drive a proliferative/differentiated phenotype and suppress invasion, and demonstrates how understanding MITF’s network could enable prediction of patient survival.  

The research also investigated the previously observed relationship between low MITF expression and an increase in tumour immune filtration, for which the mechanism was poorly understood. The authors identified that signalling through the Notch pathway is also associated with immune infiltration in mouse and human melanoma tumours. This has shed light on how immune-rich and immune-poor environments are established within tumours, with potential implications for the success or failure of anti-melanoma immunotherapies.

 

Similar stories

Funded DPhil studentships available - apply now for October 2023 entry

Ludwig Oxford research groups are recruiting DPhil candidates for the funded DPhil in Cancer Science, NDM prize studentship and Oxford-MRC Doctoral Training Partnership Industrial Case programmes commencing in October 2023

Ludwig Oxford retreat 2022 – a recap

On 13-14th June 2022, the Oxford Branch of the Ludwig Institute for Cancer Research held their annual retreat to discuss key scientific advances within the Branch and beyond.